Similar results have previously demonstrated that varying growth sensitivities to pharmacological inhibition of mitogen-activated protein kinase kinases (MEKs) do not correlate with pERK activity in KRAS and BRAF mutant CRC cell lines44,45. This evidence concerns the gene WNK2 and colorectal carcinoma.